Anna Furlan
YOU?
Author Swipe
View article: The treatment of patients primary refractory or with sub-optimal response to d-VTD induction: An italian real-life Study
The treatment of patients primary refractory or with sub-optimal response to d-VTD induction: An italian real-life Study Open
Despite the improvement in the treatment of multiple myeloma (MM) patients, there is still a consistent fraction of patients who have a primary refractory MM (PRMM) or relapse early during treatment. Up to now in Italy the treatment for ne…
View article: Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients Open
Not available.
View article: Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data Open
Not available.
View article: Overview of 1q abnormalities in multiple myeloma: scientific opinions from Italian experts
Overview of 1q abnormalities in multiple myeloma: scientific opinions from Italian experts Open
Multiple myeloma (MM) is a haematological malignancy characterised by high genomic heterogeneity. One of the most common cytogenic abnormalities in MM is the gain of genetic material at the long arm (q) of chromosome 1 (+ 1q). While many m…
View article: Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study Open
This multicenter real‐world analysis evaluated the efficacy of isatuximab, pomalidomide, and dexamethasone (IsaPd) in 51 patients with multiple myeloma (MM) who were refractory to daratumumab (Dara‐R). The majority were under 70 years old …
View article: Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials Open
Not available.
View article: HIGH DOSES OF BISPHENOL-A PROMOTE A REDUCTION IN THE NUMBER OF MYENTERIC NEURONS IN RATS
HIGH DOSES OF BISPHENOL-A PROMOTE A REDUCTION IN THE NUMBER OF MYENTERIC NEURONS IN RATS Open
Bisphenol-A (BPA), found in plastics and food coatings, is known for its potential adverse health effects. While some studies have focused on BPA's endocrine effects, other research explores its impact on the myenteric plexus, which contro…
View article: Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis
Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis Open
Introduction Isatuximab (Isa) is an anti-CD38 monoclonal antibody targeting a specific CD38 epitope and induces myeloma cell death via multiple mechanisms. Isa was approved in combination with pomalidomide and dexamethasone (Pd) and in com…
View article: Spontaneous rupture of a splenic artery pseudo-aneurysm post sleeve gastrectomy: case report
Spontaneous rupture of a splenic artery pseudo-aneurysm post sleeve gastrectomy: case report Open
Pseudo-aneurysm of the splenic artery is a rare phenomenon in young males without risk factors and its rupture represents a true emergency. This condition is difficult to diagnose because the symptomatology is often blurred and not straigh…
View article: A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience
A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience Open
Introduction Ixazomib, lenalidomide, and dexamethasone (IRd) have been approved for the treatment of relapsed/refractory multiple myeloma (RRMM) based on the results of the TOURMALINE‐MM1. Objectives and Methods We conducted a retrospectiv…
View article: Improved efficiency of daratumumab treatment of multiple myeloma adopting the subcutaneous route: A micro‐costing analysis in three Italian hematology centers
Improved efficiency of daratumumab treatment of multiple myeloma adopting the subcutaneous route: A micro‐costing analysis in three Italian hematology centers Open
Background Daratumumab is a humanized monoclonal antibody approved for the treatment of adult patients with newly diagnosed or relapsed/refractory multiple myeloma (RRMM). Subcutaneous (SC) formulation proved to be non‐inferior in comparis…
View article: Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients
Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients Open
According to 2021 ESMO guidelines, treatment of newly diagnosed (ND) transplant eligible (TE) Multiple Myeloma (MM) patients is settled by an induction phase followed by single or tandem autologous stem cell transplantation (ASCT) and Lena…
View article: Acquired Isolated Factor VII Deficiency in Plasma Cell Dyscrasias: A Brief Presentation of Two Plasma-Cell-Leukemia-Related Cases and Review of Literature
Acquired Isolated Factor VII Deficiency in Plasma Cell Dyscrasias: A Brief Presentation of Two Plasma-Cell-Leukemia-Related Cases and Review of Literature Open
Acquired isolated factor VII (FVII) deficiency is a rare but important discovery in patients with plasma cell disorders with significant therapeutic and prognostic implications. The present analysis and review of cases reported in the lite…
View article: P970: A REAL-WORLD RETROSPECTIVE-PROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OF COMBINED IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE NORTHERN ITALY EXPERIENCE
P970: A REAL-WORLD RETROSPECTIVE-PROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OF COMBINED IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE NORTHERN ITALY EXPERIENCE Open
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Ixazomib-lenalidomide and dexamethasone (IRd) has been approved for the treatment of relapsed/refractory multiple myeloma (RRMM) based on the results of the pivota…
View article: P20 LENALIDOMIDE MAINTENANCE AFTER VTD INDUCTION AND AUTOLOGOUS STEM CELL TRANSPLANTATION: PRELIMINARY RESULTS OF A REAL-LIFE STUDY INCLUDING 389 PATIENTS
P20 LENALIDOMIDE MAINTENANCE AFTER VTD INDUCTION AND AUTOLOGOUS STEM CELL TRANSPLANTATION: PRELIMINARY RESULTS OF A REAL-LIFE STUDY INCLUDING 389 PATIENTS Open
According to 2021 ESMO guidelines, treatment of newly diagnosed (ND) transplant eligible (TE) Multiple Myeloma (MM) patients is settled by an induction phase followed by single or tandem autologous stem cell transplantation (ASCT) and Lena…
View article: P49 A REAL-WORLD RETROSPECTIVE-PROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OF COMBINED IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE NORTHERN ITALY EXPERIENCE
P49 A REAL-WORLD RETROSPECTIVE-PROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OF COMBINED IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE NORTHERN ITALY EXPERIENCE Open
Ixazomib-lenalidomide and dexamethasone (IRd) has been approved for the treatment of relapsed/refractory multiple myeloma (RRMM) based on the results of the pivotal Tourmaline MM-1 trial. We conducted an observational analysis of 81 RRMM p…
View article: Prompt Hematological Recovery in Response to a Combination of Pegylated Interferon α-2a and Rituximab in a Profoundly Immuno-Suppressed Hairy Cell Leukemia Patient with a Mycobacterial Infection at Onset: Benefits and Drawbacks of Rapid Immune Reconstitution
Prompt Hematological Recovery in Response to a Combination of Pegylated Interferon α-2a and Rituximab in a Profoundly Immuno-Suppressed Hairy Cell Leukemia Patient with a Mycobacterial Infection at Onset: Benefits and Drawbacks of Rapid Immune Reconstitution Open
The present paper reports, to the best of our knowledge for the first time, the efficacy and tolerability of the combination of interferon (IFN)α-2a in pegylated formulation and rituximab after a “priming” phase with IFN in the frontline t…
View article: COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge
COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge Open
B cell-targeting strategies such as rituximab are widely used in B cell hematologic malignancies, rheumatologic and musculoskeletal diseases and a variety of autoimmune disorders. The purpose of this paper is to illustrate how exposure to …
View article: Dataset related to the article: microRNA-21/PDCD4 Proapoptotic Signaling From Circulating CD34+ Cells to Vascular Endothelial Cells: A Potential Contributor to Adverse Cardiovascular Outcomes in Patients With Critical Limb Ischemia
Dataset related to the article: microRNA-21/PDCD4 Proapoptotic Signaling From Circulating CD34+ Cells to Vascular Endothelial Cells: A Potential Contributor to Adverse Cardiovascular Outcomes in Patients With Critical Limb Ischemia Open
Dataset related to the article with title: MicroRNA-21/PDCD4 proapoptotic signaling from circulating CD34+ cells to vascular endothelial cells: a potential contributor to adverse cardiovascular outcomes in patients with critical limb ische…
View article: Dataset related to the article: microRNA-21/PDCD4 Proapoptotic Signaling From Circulating CD34+ Cells to Vascular Endothelial Cells: A Potential Contributor to Adverse Cardiovascular Outcomes in Patients With Critical Limb Ischemia
Dataset related to the article: microRNA-21/PDCD4 Proapoptotic Signaling From Circulating CD34+ Cells to Vascular Endothelial Cells: A Potential Contributor to Adverse Cardiovascular Outcomes in Patients With Critical Limb Ischemia Open
Dataset related to the article with title: MicroRNA-21/PDCD4 proapoptotic signaling from circulating CD34+ cells to vascular endothelial cells: a potential contributor to adverse cardiovascular outcomes in patients with critical limb ische…
View article: MicroRNA-21/PDCD4 proapoptotic signaling from circulating CD34+ cells to vascular endothelial cells: a potential contributor to adverse cardiovascular outcomes in patients with critical limb ischemia
MicroRNA-21/PDCD4 proapoptotic signaling from circulating CD34+ cells to vascular endothelial cells: a potential contributor to adverse cardiovascular outcomes in patients with critical limb ischemia Open
Objective. In patients with type 2 diabetes (T2D) and critical limb ischemia (CLI), migration of circulating CD34+ cells predicted cardiovascular mortality at 18 months post-revascularization. This study aimed to provide long-term validati…
View article: MicroRNA-21/PDCD4 Proapoptotic Signaling From Circulating CD34+ Cells to Vascular Endothelial Cells: A Potential Contributor to Adverse Cardiovascular Outcomes in Patients With Critical Limb Ischemia
MicroRNA-21/PDCD4 Proapoptotic Signaling From Circulating CD34+ Cells to Vascular Endothelial Cells: A Potential Contributor to Adverse Cardiovascular Outcomes in Patients With Critical Limb Ischemia Open
OBJECTIVE In patients with type 2 diabetes (T2D) and critical limb ischemia (CLI), migration of circulating CD34+ cells predicted cardiovascular mortality at 18 months after revascularization. This study aimed to provide long-term validati…
View article: MicroRNA-21/PDCD4 proapoptotic signaling from circulating CD34+ cells to vascular endothelial cells: a potential contributor to adverse cardiovascular outcomes in patients with critical limb ischemia
MicroRNA-21/PDCD4 proapoptotic signaling from circulating CD34+ cells to vascular endothelial cells: a potential contributor to adverse cardiovascular outcomes in patients with critical limb ischemia Open
Objective. In patients with type 2 diabetes (T2D) and critical limb ischemia (CLI), migration of circulating CD34+ cells predicted cardiovascular mortality at 18 months post-revascularization. This study aimed to provide long-term validati…